Scholar Rock (SRRK) PT Raised to $33 at Wedbush, After Company Releases Clinical Trial Data
Tweet Send to a Friend
Wedbush analyst David Nierengarten raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
